Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia-Reference-Cited by-同舟云学术

Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

Published:2019-06-17 Issue:8 Volume:33 Page:1835-1850
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Branford Susan, ,Kim Dennis Dong Hwan,Apperley Jane F.,Eide Christopher A.,Mustjoki Satu^ORCID,Ong S. Tiong,Nteliopoulos Georgios,Ernst Thomas,Chuah Charles,Gambacorti-Passerini Carlo^ORCID,Mauro Michael J.,Druker Brian J.^ORCID,Kim Dong-Wook,Mahon Francois-Xavier,Cortes Jorge,Radich Jerry P.,Hochhaus Andreas,Hughes Timothy P.

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/s41375-019-0512-y.pdf

Reference100 articles.

1. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. Blood. 2013;122:872–84.

2. Radich JP, Deininger M, Abboud CN, Altman JK, Berman E, Bhatia R, et al. Chronic Myeloid Leukemia, Version 1.2019, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2018;16:1108–35.

3. Ashley EA. Towards precision medicine. Nat Rev Genet. 2016;17:507–22.

4. Dohner H, Estey E, Grimwade D, Amadori S, Appelbaum FR, Buchner T, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017;129:424–47.

5. Sokal JE, Cox EB, Baccarani M, Tura S, Gomez GA, Robertson JE, et al. Prognostic discrimination in “good-risk” chronic granulocytic leukemia. Blood. 1984;63:789–99.

Cited by 105 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Significance of Somatic Mutation Profiling in CML Beyond BCR-ABL: A Retrospective Study of the Indian Population;Indian Journal of Hematology and Blood Transfusion;2024-06-21

2. Mutations in myeloid transcription factors and activated signaling genes predict chronic myeloid leukemia outcomes;Blood Advances;2024-05-17

3. Combination therapies with ponatinib and asciminib in a preclinical model of chronic myeloid leukemia blast crisis with compound mutations;Leukemia;2024-04-13

4. Single cell multi-omics analysis of chronic myeloid leukemia links cellular heterogeneity to therapy response;2024-04-05

5. BCR/ABL-Positive Chronic Myeloid Leukemia in Children: Current Treatment Approach;Current Oncology Reports;2024-02-10